alexa
Reach Us +1-504-608-2390
The Role of B Cells in Autoimmunity: Insights on B Lymphocyte Stimulation (Blys) as a Target for Biologics in Systemic Lupus Erythematosus | OMICS International | Abstract
ISSN: 2155-9899

Journal of Clinical & Cellular Immunology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

The Role of B Cells in Autoimmunity: Insights on B Lymphocyte Stimulation (Blys) as a Target for Biologics in Systemic Lupus Erythematosus

Evan S Vista* and Mark Aragones
St. Luke’s Medical Center and College of Medicine, Philippines
Corresponding Author : Evan Silverio Vista
MD, Rheumatology, Allergology and
Immunology Center MAB 1116 St Luke’s
Medical Center, Bonifacio Global City 1632, Philippines
Tel: +639175024279
E-mail: [email protected]
Received: August 10, 2015 Accepted: October 06, 2015 Published: October 15, 2015
Citation: Vista ES, Aragones M (2015) The Role of B Cells in Autoimmunity: Insights on B Lymphocyte Stimulation (Blys) as a Target for Biologics in Systemic Lupus Erythematosus. J Clin Cell Immunol 6:360. doi:10.4172/2155-9899.1000360
Copyright: © 2015 Vista ES, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at Pubmed, Scholar Google

Abstract

Systemic lupus erythematosus (SLE) is a heterogenous condition with significant impact on morbidity and mortality among affected individuals, usually young females during their most productive stage in life. The production of pathogenic autoantibodies has been the classical hallmark for the disease. B cells, the precursor of the antibody producing plasma cells, are believed to play a central role in SLE disease activity. It has long been considered a difficult disease to manage and diagnose due to its wide raging manifestations and severity. This systemic autoimmune condition has attracted many clinicians and researchers for decades in the hope of fully unraveling the disease pathogenesis in order to come up with more effective treatments. Treatment strategies have been broadly directed at dampening the immune response with consequential adverse effects in the long term care of diseased patients. An improved understanding of the role B cells play in lupus pathology has led to the development of belimumab, a monoclonal antibody which became the first successful treatment for SLE introduced after more than half a century. The drug is among the class of targeted biologic therapies now evolving in the field of rheumatology and clinical immunology. It is directed to inhibit the survival of autoreactive B cells that are implicated in SLE disease activity. This review article discusses the stages in B cell ontogeny predisposing SLE development and reports the critical role of B lymphocyte stimulator in the occurrence of SLE disease flares.

Keywords

Recommended Conferences

7th International Congress on Infectious Diseases

Berlin, Germany

4th International Conference on Mass Spectrometry

Milan, Italy
Share This Page
Top